Weide Zhong[Author] - Search Results

Year	Number of Results
2002	1
2003	2
2004	1
2006	1
2007	5
2008	10
2009	15
2010	5
2011	8
2012	11
2013	12
2014	11
2015	16
2016	9
2017	10
2018	12
2019	11
2020	13
2021	16
2022	20
2023	15
2024	7

1

Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer.

Ye J, Cai S, Feng Y, Li J, Cai Z, Deng Y, Liu R, Zhu X, Lu J, Zhuo Y, Liang Y, Xie J, Zhang Y, He H, Han Z, Jia Z, Zhong W. Ye J, et al. Among authors: zhong w. Signal Transduct Target Ther. 2023 Aug 16;8(1):303. doi: 10.1038/s41392-023-01516-2. Signal Transduct Target Ther. 2023. PMID: 37582751 Free PMC article.

2

Molecular predictors of metastasis in patients with prostate cancer.

Lin J, Zhuo Y, Zhang Y, Liu R, Zhong W. Lin J, et al. Among authors: zhong w. Expert Rev Mol Diagn. 2023 Mar;23(3):199-215. doi: 10.1080/14737159.2023.2187289. Epub 2023 Mar 8. Expert Rev Mol Diagn. 2023. PMID: 36860119 Review.

3

Tumor-derived lymphangiogenic factors and lymphatic metastasis.

Cao Y, Zhong W. Cao Y, et al. Among authors: zhong w. Biomed Pharmacother. 2007 Oct;61(9):534-9. doi: 10.1016/j.biopha.2007.08.009. Epub 2007 Sep 14. Biomed Pharmacother. 2007. PMID: 17904785 Review.

4

A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism.

Liu R, Feng Y, Deng Y, Zou Z, Ye J, Cai Z, Zhu X, Liang Y, Lu J, Zhang H, Luo Y, Han Z, Zhuo Y, Xie Q, Hon CT, Liang Y, Wu CL, Zhong W. Liu R, et al. Among authors: zhong w. J Exp Clin Cancer Res. 2021 Jun 7;40(1):188. doi: 10.1186/s13046-021-01996-6. J Exp Clin Cancer Res. 2021. PMID: 34098990 Free PMC article.

5

FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2α blockade by facilitating LDHA phosphorylation.

Liu R, Zou Z, Chen L, Feng Y, Ye J, Deng Y, Zhu X, Zhang Y, Lin J, Cai S, Tang Z, Liang Y, Lu J, Zhuo Y, Han Z, Ling X, Liang Y, Wang Z, Zhong W. Liu R, et al. Among authors: zhong w. Cell Death Dis. 2024 Jan 17;15(1):64. doi: 10.1038/s41419-024-06450-x. Cell Death Dis. 2024. PMID: 38233415 Free PMC article.

6

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.

Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y. Ren S, et al. Among authors: zhong w. Eur Urol. 2018 Mar;73(3):322-339. doi: 10.1016/j.eururo.2017.08.027. Epub 2017 Sep 18. Eur Urol. 2018. PMID: 28927585

7

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

Li M, Bai G, Cen Y, Xie Q, Chen J, Chen J, Chen Q, Zhong W, Zhou X. Li M, et al. Among authors: zhong w. J Transl Med. 2023 Dec 6;21(1):884. doi: 10.1186/s12967-023-04743-x. J Transl Med. 2023. PMID: 38057852 Free PMC article.

8

Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer.

Feng Y, Deng Y, Tang Z, Cai S, Li J, Liu R, Wan J, He H, Zeng G, Ye J, Han Z, Zhong W. Feng Y, et al. Among authors: zhong w. Front Endocrinol (Lausanne). 2023 Mar 16;14:1148898. doi: 10.3389/fendo.2023.1148898. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37008945 Free PMC article.

9

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer.

Zeng J, Chen J, Li M, Zhong C, Liu Z, Wang Y, Li Y, Jiang F, Fang S, Zhong W. Zeng J, et al. Among authors: zhong w. Front Pharmacol. 2023 May 24;14:1191129. doi: 10.3389/fphar.2023.1191129. eCollection 2023. Front Pharmacol. 2023. PMID: 37292153 Free PMC article.

10

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

Liang Y, Yin W, Cai Z, Luo H, Liu Q, Zhong C, Chen J, Lin Z, Huang Y, Liang Z, Deng J, Zhong W, Cai C, Lu J. Liang Y, et al. Among authors: zhong w. Hum Genet. 2023 Sep 27. doi: 10.1007/s00439-023-02603-8. Online ahead of print. Hum Genet. 2023. PMID: 37758909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

191 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Results by year